Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | CES2 | O00748 | 4/20 | 0.62 |
| ▸ | CES1 | P23141 | 4/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.59 |
| ▸ | PPARG | P37231 | 7/20 | 0.59 |
| ▸ | PPARD | Q03181 | 7/20 | 0.59 |
| ▸ | PPARA | Q07869 | 7/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.59 |
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TLR2 | O60603 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | FABP4 | P15090 | 2/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.59 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2782616 | 1.00 | KMT2A (0.65) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL6840834 | 1.00 | KMT2A (0.65) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL888107 | 1.00 | KMT2A (0.65) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL105548 | 1.00 | KMT2A (0.65) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL811181 | 1.00 | KMT2A (0.65) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL19629035 | 1.00 | KMT2A (0.65) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL632531 | 1.00 | KMT2A (0.65) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL1153187 | 1.00 | KMT2A (0.65) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL21044695 | 1.00 | KMT2A (0.65) | KMT2AMAPTCES2CES1GPR84 | |
| SCHEMBL21044630 | 1.00 | KMT2A (0.65) | KMT2AMAPTCES2CES1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375669-A | Monoterpene lactone compound, preparation method thereof and application thereof in preparation of anticomplement medicines | 复旦大学 | 2023-07-04 | — | — | CN | claimed |
| CN-108929400-B | Nickel catalyst system, high-performance polybutadiene and preparation method thereof | 北京化工大学 | 2023-03-14 | — | — | CN | claimed |
| CN-115043926-A | Polypeptide fragment targeting GSDMD and application thereof in preparation of medicines for preventing and treating cell apoptosis and sepsis | 中国科学技术大学 | 2022-09-13 | — | — | CN | claimed |
| CN-114989637-A | Functionalized zirconia, preparation method thereof and optical film | 山东国瓷功能材料股份有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-113025283-B | Phase change material, preparation method thereof and electronic component | 东莞新能德科技有限公司 | 2022-06-17 | — | — | CN | claimed |
| CN-113025283-A | Phase-change material, preparation method thereof and electronic component | 东莞新能德科技有限公司 | 2021-06-25 | — | — | CN | claimed |
| EP-2893355-B1 | KIT AND METHOD FOR QUANTITATIVE DETECTION OF STEROIDS | UNIV SWANSEA (GB) | 2019-06-05 | — | — | EP | claimed |
| US-9797065-B2 | Process of forming a crystal having a particular shape and the crystal formed by the process | ARIESANTI ELSA (US) | 2017-10-24 | — | — | US | claimed |
| CN-106999502-A | Pharmaceutical composition and method | 来普卡公司 | 2017-08-01 | — | — | CN | claimed |
| CN-104902919-A | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists | SANOFI SA | 2015-09-09 | — | — | CN | claimed |
| US-20130040095-A1 | PROCESS OF FORMING A CRYSTAL HAVING A PARTICULAR SHAPE AND THE CRYSTAL FORMED BY THE PROCESS | ARIESANTI ELSA (US) | 2013-02-14 | — | — | US | claimed |
| US-20090130051-A1 | Flavonoid Compounds and Uses Thereof | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2009-05-21 | — | — | US | claimed |
| CN-1784423-A | Peptides for use in treating obesity | NOVO NORDISK AS (DK) | 2006-06-07 | — | — | CN | claimed |
| CN-1675231-A | Process for producing alkylaminoglucoside phosphate and disaccharide immunoeffectors and intermediates thereof | CORIXA CORP A CORP OF THE STAT (US) | 2005-09-28 | — | — | CN | claimed |
| EP-1242444-B1 | PROCESS FOR PREPARING 17ALPHA-ACETOXY-11BETA- 4-N,N-(DIMETHYLAMINO)PHENYL]-21-METHOXY-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE PROCESS, AND PROCESSES FOR PREPARING SUCH INTERMEDIATES | US GOV HEALTH & HUMAN SERV (US) | 2005-07-20 | — | — | EP | claimed |
| EP-1365705-A1 | INJECTABLE PHARMACEUTICAL COMPOSITION COMPRISING MICROPARTICLES OR MICRODROPLETS OF CAMPTOTHECIN | SuperGen, Inc. (US) | 2003-12-03 | — | — | EP | claimed |
| WO-2002064064-A1 | INJECTABLE PHARMACEUTICAL COMPOSITION COMPRISING MICROPARTICLES OR MICRODROPLETS OF CAMPTOTHECIN | SUPERGEN, INC. (US) | 2002-08-22 | — | — | WO | claimed |
| EP-0488383-B1 | 2-beta,19-ethylene bridged steroids as aromatase inhibitors | MERRELL PHARMA INC (US) | 1996-09-11 | — | — | EP | claimed |
| EP-0201452-B1 | PROCESS FOR THE PREPARATION OF 17-ALPHA-ETHYNYL-17-BETA-HYDROXY-18-METHYL-ESTRA-4,15-DIEN-3-ONE AND THE STARTING PRODUCTS FOR THIS PROCESS | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-08-09 | — | — | EP | claimed |
| EP-0140904-B1 | PROCESS AND COMPOSITION FOR PLANT GROWTH REGULATION | NITROKEMIA IPARTELEPEK (HU) | 1988-08-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130051-A1 | Flavonoid Compounds and Uses Thereof | CAT, NQO1, GPX4 | KMT2A 4797/4885MAPT 3887/4885CES2 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.